8-K current report · filed Oct 29, 2026

Teva Pharmaceutical Industries Ltd (TEVA) 8-K Current Report: October 29, 2026

Item 5.02TEVA overview

Short answer

Teva Pharmaceutical Industries Ltd (TEVA) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Dr. David J. Brailer elected independent director, effective November 3, 2026, through Teva’s 2027 annual meeting.

Teva Pharmaceutical Industries Ltd 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Dr. David J. Brailer elected independent director, effective November 3, 2026, through Teva’s 2027 annual meeting
  • Expected committee assignments: Human Resources and Compensation, Compliance
  • Health-tech and healthcare policy expertise adds strategic perspective to Teva’s board
  • Standard non-executive director compensation, with no disclosed related-party interests or election arrangements

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Teva Pharmaceutical Industries Ltd 8-K filings

Get the next TEVA 8-K as it lands

Follow TEVA for push alerts, or ask the research agent what this filing means.